Trials / Completed
CompletedNCT01162590
Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults
Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy adults aged 18 to 45 years in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotarix ™ | Oral, single dose |
| BIOLOGICAL | Placebo | Oral, single dose |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-03-31
- Completion
- 2010-03-31
- First posted
- 2010-07-14
- Last updated
- 2017-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01162590. Inclusion in this directory is not an endorsement.